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ABSTRACT

Oxaliplatin is an anticancer drug that reacts with DNA, RNA, and proteins both in
vitro and in vivo. Our research focuses on synthesizing analogs of oxaliplatin and
understanding how bulky ligand groups affect reaction with amino acids. (R,R)-N,N’dimethyl-1,2-diaminocyclohexane platinum(II) oxalate or Pt(Me2dach)(ox) varies from
oxaliplatin or Pt(dach)(ox) in that it has one methyl group attached to each platinum
coordinated nitrogen. Nuclear Magnetic Resonance (NMR) spectroscopy has shown that
the reactions of N-Acetylmethionine (N-AcMet) with Pt(Me2dach)(ox) and Pt(dach)(ox)
proceed at similar rates suggesting that the methyl groups of Pt(Me2dach)(ox) have little
effect on the initial reaction. Whereas the reaction of Pt(dach)(ox) and N-AcMet can form
1:1 or 1:2 complexes, Pt(Me2dach)(ox) with N-AcMet can form only 1:1 products.
Depending on the Pt:N-AcMet ratios, Pt(dach)(ox) has the potential to form either a
[Pt(dach)(N-AcMet-S)2] or [Pt(dach)(N-AcMet-S,N)] complex. The bis product is not
found in Pt(Me2dach)(ox) reactions because the formation of a [Pt(Me2dach)(N-AcMetS,O)]+ product hinders the coordination of a second N-AcMet. It has therefore been
deduced that the additional methyl groups of Pt(Me2dach)(ox) limit reaction with NAcMet to a 1:1 molar product.

Keywords: Oxaliplatin, Cancer, Platinum, Nuclear Magnetic Resonance, Proteins
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Dedicated to those trying to connect the dots.
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CHAPTER 1

INTRODUCTION

Cisplatin, (SP-4-2)-Diamminedichloroplatinum, cis-DDP is an anticancer drug
that was first synthesized by Michael Peyrone in 1845. However, the chemotherapeutic
activity of the drug wasn’t discovered until more than a century later, in 1970, when
Barnett Rosenberg and his research team inadvertently stumbled upon it. The research
team was studying the growth of Escherichia coli, a type of bacteria, in the presence of
an electric current. Platinum electrodes were used to establish electric fields, due to their
inertness, and the E. coli did not divide, but rather elongated. It was determined that this
anomaly was caused by the reaction of the platinum electrodes with agents in the
bacterial solution, rather than by the electric current [1].
The drug gained popularity as studies showed that cisplatin was a
multidimensional anti-carcinogenic agent inhibiting the metastasis of testicular, ovarian,
lung, and stomach cancers. During clinical research, cisplatin displayed negative side
effects including but not limited to nephrotoxicity, neurotoxicity, and low blood mineral
levels [1-2]. This discovery prompted investigation into safer cisplatin analogs with
similar anticancer activity. Whereas cisplatin displays chemotherapeutic activity, its
stereoisomer transplatin does not, for reasons discussed later.

1

The second generation anticancer drug carboplatin, cis-Diammine(1,1cyclobutanedicarboxylato)platinum(II), was discovered in the late 1980s. Following FDA
approval in 2003, the drug entered the market under the trade name Paraplatin. The drug
was found effective in fighting ovarian and non-small cell lung cancers [3]. Side effects
of using carboplatin were greatly reduced in comparison to its parent cisplatin [4].

Carboplatin
H

3

H3

Cisplatin
3H

H3

Oxaliplatin

(R,R) Me 2 dach Oxalate

Figure 1.1. Skeletal Structures of Platinum Compounds.
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The third generation antineoplastic drug oxaliplatin was discovered in Japan in
1976 by Kidani [6]. It became FDA approved in 2002 taking on the trade name Eloxatin
[7]. Eloxatin is used in combination with 5-fluorouracil and leucovorin to treat colorectal
cancer [8].
These platinum based drugs are alkylating-like agents subcategorized as metallic
salts that exhibit anticancer activity by targeting cells with expedited replication. Due to
the influx of agents in rapidly dividing cells, chemotherapy drugs are often uptaken;
platinum based drugs bind to DNA and bend it thereby inhibiting transcription and
further replication. They are cell cycle non-specific meaning they affect cells at rest [9].
Cisplatin, carboplatin, and oxaliplatin each react by the same mechanism, and are
administered via intravenous (IV) injection. Once in the blood these compounds circulate
in their inert forms – chlorides on cisplatin, biscarboxylate on carboplatin, oxalate on
oxaliplatin – with the potential to react with proteins and other agents [10]. Platinum(II)
compounds have a high kinetic affinity for binding proteins, and these interactions may
play critical roles in oxidative stress [11], cellular uptake [12], or resistance pathways
[13]. There is currently no certainty as to how these cytotoxic agents enter a cell; one
suggestion is that these drugs passively diffuse into cells or get uptaken by the human

1,2 – Diaminocyclohexane Pt(II) Dichloride
1,2 – Diaminocyclohexane Pt(II) Oxalate
N,N’ – Dimethyl – 1,2 –Diaminocyclohexane Pt(II) Dichloride
N,N’ – Dimethyl – 1,2 –Diaminocyclohexane Pt(II) Oxalate
N-Acetylmethionine
Deoxyribonucleic Acid
Ribonucleic Acid
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Dach Dichloride
Dach Oxalate or Oxaliplatin
Me2dach Dichloride
Me2dach Oxalate
N-AcMet
DNA
RNA

copper transporter 1 (hCTR1) [14].
CTR1 is a transmembrane hydrophilic copper transporter. It forms as a
homotrimer leaving a pore composed of cysteines, methionines, and histidines through
which copper passes. Methionines 150 and 154, and histidine 139 transport Cu(I) down a
concentration gradient via transchelation reactions [15]. Platinum based drugs may be
uptaken using the same mechanism, and the fact that platinum based compounds are
attracted to the nucleophilic sulfur sites of cysteine and methionine residues strengthens
this idea[16]. The attraction of sulfur and platinum can also be explained using Hard-Soft
Acid-Base theory, which states that hard acids prefer to interact with hard bases and soft
acids with soft bases. Platinum, being a 5d transition metal is considered a soft acid while
sulfur is a known as a soft base, hence the strong interaction. Whereas lack of CTR1
expression leads to resistance of cisplatin, carboplatin, and oxaliplatin in mammalian and
yeast cells, overexpression enhances cellular recognition of their toxic effects thereby
increasing influx of these agents [17]. This demonstrates a direct link between CTR1 and
the anticancer activity of these platinum drugs.
Once inside the cell, these compounds become aquated e.g., cisplatin forming
[Pt(NH3)2(H2O)Cl]1+ and ultimately [Pt(NH3)2(H2O)2]2+. Once they become positively
charged and incapable of crossing the hydrophobic membrane, they are trapped within
the cell and passively diffuse into the nucleus. The two most nucleophilic regions of
DNA base pairs are the N7-positions of guanine and adenine. It is here where platinum
complexes forms interstrand or intrastrand cross bridges with DNA. Potential cross-links
include 1,2-intrastrand, 1,3-intrastrand, 1,2-interstrand, and DNA-protein adducts.
4

Figure 1.2. Visual Depiction of the Copper Transporter 1 homotrimer [14]

1,2-intrastrand cross-links form 90o angles between two adjacent guanine or adenine
residues and the platinum atom, which bends the DNA duplex towards the major groove.
This exposes the minor groove of the DNA strand to which multiple classes of proteins
can bind, such as the damage recognition proteins human upstream binding factor (UBF),
TATA box-binding proteins (TBP), and high-mobility group box proteins (HMGB1), and
mismatch-repair proteins [14]. HMG-domain proteins have a high affinity for platinumguanine, guanine adducts [18] and binding leads to inhibition of nucleotide excision
repair, transcription, and replication, consequentially warranting apoptosis [14]. This
leads to chemotherapeutic activity and tumor reduction.

5

Figure 1.3. Potential cross-links of platinum drugs: (a) 1,2-interstrand (b) 1,2intrastrand (c) 1,3-intrastrand (d) DNA-protein adduct

As previously described, these drugs have the ability to bind with DNA and/or
proteins [19]. Our lab focuses on the reactions of oxaliplatin and its derivatives with
different amino acids found within select proteins. Previous research has shown that
platinum based chemotherapeutic drugs react with proteins located in the blood, cytosol,
or embedded in membranes. Research is aimed at identify how much bulk can be added
to oxaliplatin analogs before slowing down such reactions. It is speculated that bulk
amount and anticancer activity are inversely related. The current analog we are studying,
6

(R,R)-N,N’-dimethyl-1,2-diaminocyclohexane platinum(II) oxalate or Pt(Me2dach)(ox) is
being studied and characterized upon reaction with N-Acetylmethionine (N-AcMet). It
differs from oxaliplatin in that it has one methyl group attached to each of the platinum
coordinating nitrogen atoms.
We have found that the additional bulk of Pt(Me2dach)(ox) does slow reaction
with N-AcMet, but minimally. Pt(dach)(ox) has the ability to coordinate to two amino
acids in a 1:2 Pt:N-AcMet ratio, but the bulk of Pt(Me2dach)(ox) limits reaction to a 1:1
product in the form of a S,O-chelate. This could either prevent the compound from
entering the cell by hindering transchelation reactions within the hCTR1 or block the
molecule from forming Pt-DNA complexes.
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CHAPTER 2

METHODOLOGY
A JEOL Eclipse 500 MHz NMR Spectrometer was used to obtain 1H and 195Pt
NMR spectra. Deuterium Oxide (D2O) was used as a standard reference.

Several syntheses were common throughout this research in order to obtain:
Silver Oxalate
Silver oxalate was synthesized by mixing 350 mg oxalic acid (C2H2O4) with 1
g of silver nitrate (AgNO3) in 20 mL DI H2O (1.5 mM AgNO3: 1 mM C2H2O4)
in an amber vial. After stirring for approximately 30 minutes the milky white
precipitate was run through a vacuum filtration apparatus for 5-10 minutes. The
vial was rinsed with ethanol to get all Ag2C2O4 out and once dry, the solid was
collected. Yield = 798.8 mg.

Oxalic Acid

Silver Nitrate

Silver Oxalate
2-

2

FIGURE 2.1. Synthesis of silver oxalate.
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(R,R)-1,2-Diaminocyclohexane Platinum(II) Dichloride
The synthesis of Dach Dichloride required making two separate solutions.
Solution 1 consisted of 64 mg dach ligand and 5 mL of methanol in a 10 mL
beaker. Solution 2 involved mixing 232 mg (equi-molar amount) of potassium
tetrachloroplatinate (K2PtCl4) and 5 mL of DI H2O in an amber vial. Solution
2 was added drop-wise to solution 1 while stirring. After stirring for 2-3 hours, the
precipitate was collected by vacuum filtration and rinsed with water, ethanol,
and ether. Yield = 149 mg yellow solid.
Potassium Tetrachloroplatinate

Dach Ligand

Dach Pt(II) Dichloride

22 KCl (aq)

2

FIGURE 2.2. Synthesis of Dach Dichloride
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(R,R)-1,2-Diaminocyclohexane Platinum(II) Oxalate
In an amber vial, equimolar amounts of Dach Dichloride and silver oxalate were
dissolved in 35 mL of DI H2O (100 mg Dach Dichloride and 80 mg silver oxalate
was standard). They sample was put on a stir plate for two days or until
completely mixed. Once properly mixed, the sample was filtered via syringe
and a 0.2 micron non-disposable filter into a 50 mL round bottom flask to remove
the AgCl(s) precipitate. At this point, a laser pointer was used to check for
undissolved suspension. If clear, the solution was dehydrated using a rotary
evaporator and collected. Yield = 78.1 mg.

Silver Oxalate

Dach Dichloride

Oxaliplatin

2H

H

2

2 AgCl (s)
H

H

FIGURE 2.3. Synthesis of oxaliplatin.
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(R,R)-N,N’-Dimethyl-1,2-Diaminocyclohexane Platinum(II) Dichloride
The synthesis of Me2dach Dichloride required making two separate
solutions. Solution 1 consisted of 56.8 mg Me2dach ligand and 5 mL of
methanol in a 10 mL beaker. Solution 2 involved mixing 166 mg (equimolar amount) of potassium tetrachloroplatinate (K2PtCl4) and 5 mL of
DI H2O in an amber vial. Solution 2 was added drop-wise to solution 1
while stirring. After stirring for 2-3 hours, the yellow solution was run
through a vacuum filtration apparatus and rinsed with water, ethanol,
and ether. Yield = 124.5 mg.
Potassium Tetrachloroplatinate

Me 2 dach Ligand

Me 2 dach Pt(II) Dichloride

22 KCl (aq)

2

FIGURE 2.4. Synthesis of Me2dach Dichloride.
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(R,R)-N,N’-Dimethyl-1,2-Diaminocyclohexane Platinum(II) Oxalate
In an amber vial equimolar amounts of Me2dach Dichloride and silver oxalate
were dissolved in 35 mL of DI H2O (84.8 mg Me2dach Dichloride and 61.7 mg
silver oxalate was standard). They were then put on a stir plate for two days
or until completely mixed. Once properly mixed, the sample was filtered via
syringe using a 0.2 micron non-disposable filter into a 50 mL round bottom
flask to remove AgCl(s) precipitate. At this point, a laser pointer was used to check
for undissolved suspension. If clear, the solution was dehydrated using a rotary
evaporator. Yield = 75.1 mg.

Me 2 dach Pt(II) Dichloride

Me 2 dach Oxalate

Silver Oxalate

2-

2 AgCl (s)

2

FIGURE 2.5. Synthesis of Me2dach Oxalate
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These syntheses were run and reacted with N-AcMet in the following solutions to
observe product formations and reaction kinetics. Using the results, we have
characterized these reactions and shown that Pt(Me2dach)(ox) is limited to the formation
of a mono-product, whereas Pt(dach)(ox) can form two products.

*Solution A = Dissolved 3.4 mg Me2dach Oxalate in 1.2 mL D2O.
*Solution B = Dissolve 3.8 mg N-AcMet in 1.0 mL D2O.

600 µL NMR samples were prepared for various Pt:N-AcMet ratios:
1:1 Molar Ratio

1:2 Molar Ratio

5:1 Molar Ratio

300 µL Solution A

300 µL Solution A

750 µL Solution A

200 µL D2O

100 µL D2O

200 µL D2O

100 µL Solution B

200 µL Solution B

50 µL Solution B
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CHAPTER 3

RESULTS

Coalescence of S-CH3
signal upon heating

FIGURE 3.1. Partial 1H NMR Spectra of 3.33 mM Pt(dach)(ox) and 6.66 mM NAcMet (1:2). The Y-axes are scaled to the tallest peak and the * indicates the S-CH3
interaction.
The signals at 2.56 and 2.58 ppm coalesce upon heating to 50oC and represent the sulfurmethyl hydrogens upon Pt(dach)(N-AcMet-S2)]formation. The peak at 2.02 ppm
indicates the Ac-CH3 resonances.
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Unreacted N-AcMet

Stereochemical signals
of S-CH3 interaction

Formation of
Pt(dach)(N-AcMet-S)

FIGURE 3.2. Partial 1H NMR spectra of 3.33 mM Pt(dach)(ox) and 3.33 mM NAcMet (1:1). Y-axes are scaled to the tallest peak and the * indicates the S-CH3
signals of a S,N-chelate.

The three signals at 2.30, 2.37, and 2.43 ppm indicate the sulfur-methyl hydrogens after
formation of a [Pt(dach)((N-AcMet-S,N)] complex, while the signal at 2.02 ppm
respresents the overlap of Ac-CH3 resonances [20]. Additionally, the sharpened bisproduct signal appears upon heating reaction, suggesting a mixture of products for an
equimolar ratio reaction.
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Doublet of
doublets

Pair of doublet
of doublets

FIGURE 3.3. Partial 1H NMR spectrum of 10 mM Pt(Me2dach)(ox)and 10 mM NAcMet (1:1). Y-axes are scaled to the tallest peak.

Three doublet of doublets appear between 5.7-5.9 ppm, which are characteristic of the NAcMet alpha-hydrogen upon formation of the S,O-chleate [21].
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FIGURE 3.4. Partial 1H NMR spectra of [Pt(Me2dach)(N-AcMet-S,O)]+ at varied
temperatures.

The resonances of [Pt(Me2dach)(N-AcMet-S,O)]+ broaden with increased temperature,
suggesting several species undergoing chemical exchange based on the chirality of the
sulfur atom in the S,O-chelate.
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a.)

b.)

FIGURE 3.5. Partial 1H NMR spectra of 5 mM a.) Pt(dach)(ox) and b.)
Pt(Me2dach)(ox) reacted with 1 mM of N-AcMet. Each compound’s time points are
scaled to the same factor and * represents unreacted N-AcMet.

As seen, oxaliplatin and Me2dach Oxalate react at a similar rate. Each of these react with
a half-life of approximately one hour , while after 4 hours, N-AcMet has nearly
completely reacted.
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CHAPTER 4

DISCUSSION

We have found that Pt(dach)(ox) has the capability to form 1:1 and 1:2 Pt: NAcMet products whereas our novel compound Pt(Me2dach)(ox) is limited to a 1:1 molar
ratio due to the formation of a [Pt(Me2dach)(ox)(N-AcMet-S,O)]+ complex. Figure 3.1
shows the reaction of oxaliplatin with N-AcMet in a 1:2 molar ratio. As illustrated by the
figure, we raised the temperature to 50o C to speed up the reaction and found the
formation of a [Pt(dach)(N-AcMet-S)2] complex. The formation of this bis-product can
be seen by the attenuation of the unreacted N-AcMet peaks and formation of product
peaks, as well as the signals indicated by the asterisk. The asterisks represent the peaks
that correspond to the S-CH3 interactions of our bis-product. This was further
characterized using 195Pt NMR spectroscopy, which showed a peak at -3739 parts per
million (ppm). This chemical shift falls in the range of -3600 to -3800 – the precedent for
a PtN2S2 coordination environment [21, 22, 23].
FIGURE 3.2. shows the reaction of Pt(dach)(ox) with N-AcMet in a 1:1 molar
ratio. We have deduced that this particular reaction forms two products – [Pt(dach)(NAcMet-S,N)] and [Pt(dach)(N-AcMet-S2)]. Again, we note the attenuation of the
unreacted N-AcMet peaks around 1.95 and 2.1 ppm. After 24 hours we see the formation
of three product peaks between 2.3-2.43 ppm and after 48 hours the same peak from
19

FIGURE 3.1. arises. As previously characterized by Barnham et al., three peaks within
this range are indicative of the sulfur-methyl hydrogens upon formation of a S,N-chelate
[20]. Furthermore, the 195Pt spectrum showed signals at -3215 and -3260, which are
characteristic of a PtN3S coordination environment [21, 22].
FIGURE 3.3. is part of the 1H NMR spectrum for the 1:1 Pt(Me2dach)(ox):NAcMet reaction. There are two doublets of doublets visible around 5.7 ppm and another
doublet of doublets at 5.8 ppm that are characteristic of the alpha-hydrogen of a S,Ochelate [17, 23]. The series of peaks between 2.4-2.7 ppm signify the sulfur-methyl
hydrogens from the various stereoisomeric intermediate products of the sulfur atom. 195Pt
NMR signals at -2870 and -2890 ppm are within the benchmark range of -2600 to -2900
ppm for a typical PtN2SO coordination environment. After raising the temperature, as
seen in FIGURE 3.4., the resonances broadened suggesting multiple species undergoing
chemical exchange, thus strengthening the conclusion drawn from the peaks at 2.4-2.7
ppm in FIGURE 3.3..
Upon characterizing the reaction of Pt(Me2dach)(ox) with N-AcMet in different
molar ratios, we found our data to be consistent throughout. Therefore, we have deduced
that the additional bulk or methyl groups of Pt(Me2dach)(ox) limits the reaction to a 1:1
product in the form of [Pt(Me2dach)(N-AcMet-S,O)]+. This would prevent the platinum
complex from binding with DNA or proteins, inhibiting some of its aforementioned
functions.
In addition to characterizing the reactions of oxaliplatin and our anolog Me2dach
oxalate in different molar ratios with N-AcMet, we have also kinetically studied these
20

reactions. FIGURE 3.5. shows the reactions of both Pt(Me2dach)(ox) and Pt(dach)(ox)
with N-AcMet in 5:1 Pt:N-AcMet molar ratios over four hours. In each, we see the
attenuation of initial peaks and the complete formation of product signals after 4 hours.
Therefore, we have concluded that Pt(Me2dach)(ox) and Pt(dach)(ox) react at similar
rates, despite the fact that they form different products upon reaction with N-AcMet [24].
Our lab has previously studied another diamine compound pair –
ethylenediamine platinum(II) dinitrate or Pt(en)(NO3)2 and N,N,N’,N’tetramethylethylenediamine platinum(II) dinitrate or Pt(Me4en)(NO3)2 . Similar to our
present compound Pt(Me2dach)(ox), Pt(Me4en)(NO3)2 has additional methyl groups
attached to the secondary amine atoms. Interestingly, the additional bulk of
Pt(Me4en)(NO3)2 limits product formation to a [Pt(Me4en)(N-AcMet-S,O)]2+. Conversely,
Pt(en)(NO3)2 forms both bis-prodcuts and mono-products, similar to Pt(dach)(ox). As
noted previously, the additional methyl groups of Pt(Me2dach)(ox) did not have a
significant effect on reaction kinetics; on the contrary the four methyl groups of
Pt(Me4en)(NO3)2 slow reaction nearly 16-fold in comparison to Pt(en)(NO3)2 [21]. These
comparisons do not provide a conclusive relationship between substituent bulk and
reaction rate, but demonstrate influence on product formation.
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